优化抗体PET成像:纳米抗体与微抗体样PET示踪剂的临床前对比分析
本研究将靶向人TIGIT的纳米抗体改构为微抗体样蛋白(minabody),并与纳米抗体在体外结合、特异性、稳定性及铜-64、镓-68、氟-18标记后的PET/CT显像中头对头比较。微抗体样格式亲和力更高,但纳米抗体作为PET示踪剂特异性更高,铜-64标记纳米抗体在注射后1至48小时可显像TIGIT表达,且肿瘤摄取与对比度优于镓-68和氟-18。
要点
- 微抗体样格式的 binding 亲和力高于纳米抗体格式
- 纳米抗体格式PET示踪特异性更高,铜-64标记后1至48小时可显像TIGIT表达
- 铜-64标记纳米抗体的肿瘤摄取与对比度优于镓-68和氟-18
核心结论
- 本研究首次对微抗体样格式与纳米抗体格式用于PET显像进行头对头比较。
- 结果表明需同时考虑靶向载体格式与放射性核素才能实现准确高质量的PET显像。
研究设计与样本
- 将既往开发的人TIGIT靶向纳米抗体改构为微抗体样格式,以实现两种格式的头对头比较。
- 在体外比较微抗体样与纳米抗体格式的结合、特异性和稳定性。
- 用铜-64、镓-68或氟-18标记微抗体样和/或纳米抗体格式,通过PET/CT随时间对人TIGIT表达肿瘤进行无创显像。
主要发现
- 微抗体样格式的结合亲和力高于纳米抗体格式。
- 尽管结合亲和力较低,纳米抗体格式作为PET显像示踪剂表现优于微抗体样格式,特异性更高,铜-64标记后注射后1至48小时可显像人TIGIT表达。
- 铜-64标记纳米抗体显像的肿瘤摄取和对比度优于镓-68和氟-18。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Positron emission tomography remains the most important medical imaging technique for noninvasive imaging. Advances in radiotracer design, particularly those based on antibody(-formats), have broadened diagnostic applications. While minibodies and nanobodies stand out among antibody-type radiotracers due to their unique characteristics and pharmacokinetics, a direct comparison between these formats remains unexplored. In this study, we generated a so-called minabody, a minibody-like protein consisting of a nanobody fused to a CH3 domain, and compared it with its nanobody counterpart in vitro and in vivo upon labeling with various PET radionuclides. METHODS: A previously developed human TIGIT-targeting nanobody was reformatted to a minabody format to allow head-to-head comparison of both formats. The minabody and nanobody formats were compared in vitro for binding, specificity and stability. The minabody and/or nanobody formats were labeled with copper-64, gallium-68 or fluor-18 for non-invasive imaging of human TIGIT-expressing tumors by PET/CT over time. RESULTS: The minabody format showed higher binding affinities compared to the nanobody format. Despite lower binding affinity, the nanobody format outperformed the minabody format as PET imaging tracer showing higher specificity and allowing imaging of human TIGIT expression from 1 to 48 h post-injection upon labeling with copper-64. In addition, copper-64 showed superior tumor uptake and contrast for nanobody imaging compared to gallium-68 and fluor-18. CONCLUSION: This study describes the first head-to-head comparison between the minibody and nanobody format for PET imaging. Our results underscore the importance of considering both targeting vector format and the radionuclide to achieve accurate and high-quality PET imaging.
引用
- Zeven K, Dierick H, Sevenois M, et al. Optimizing antibody PET imaging: a comparative preclinical analysis of nanobody and minibody-like PET tracers. Eur J Nucl Med Mol Imaging. 2025. PMID: 40159541. doi:10.1007/s00259-025-07205-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。